drugset / Trial / NCT04853524
A Study of JNJ-56136379 in Healthy Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect of multiple-dose JNJ-56136379 on the single-dose pharmacokinetics (PK) of the combination of bictegravir (BIC), emtricitabine (FTC), tenofovir alafenamide (TAF) in healthy adult participants.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2021-06-15
- Completion
- 2021-07-30
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bictegravir | Small molecule | — | Oral |
| Subject | bersacapavir | Other / unclassified | — | Oral |
| Subject | emtricitabine | Other / unclassified | — | Oral |
| Subject | tenofovir alafenamide | Small molecule | — | Oral |
Indications
No indication recorded.